Meta H M Diekstra1, Jesse J Swen1, Hans Gelderblom2, Henk-Jan Guchelaar1. 1. a Department of Clinical Pharmacy and Toxicology , Leiden University Medical Center , Leiden , Netherlands. 2. b Department of Medical Oncology , Leiden University Medical Center , Leiden , Netherlands.
Abstract
OBJECTIVE: The individual response to targeted tyrosine kinase inhibitors (TKIs) in the treatment of metastatic renal cell cancer (mRCC) is highly variable. Outlined in this article are findings on potential biomarkers for TKI treatment outcome in mRCC and an evaluation of the status of clinical implementation. METHODS: Articles were selected by two independent reviewers using a systematic search in five medical databases on renal cell carcinoma, TKIs, and pharmacogenetics. RESULTS: Many researchers have focused on predictive biomarkers for treatment outcome of targeted therapies in mRCC patients. Attempts to explain differences in efficacy and toxicity of TKIs by use of genetic variants in genes related to the pharmacokinetics and pharmacodynamics of the drug have been successful. CONCLUSION: Most findings on potential biomarkers have not been validated and therefore biomarker testing to guide choice of therapy and dose in mRCC is not yet feasible.
OBJECTIVE: The individual response to targeted tyrosine kinase inhibitors (TKIs) in the treatment of metastatic renal cell cancer (mRCC) is highly variable. Outlined in this article are findings on potential biomarkers for TKI treatment outcome in mRCC and an evaluation of the status of clinical implementation. METHODS: Articles were selected by two independent reviewers using a systematic search in five medical databases on renal cell carcinoma, TKIs, and pharmacogenetics. RESULTS: Many researchers have focused on predictive biomarkers for treatment outcome of targeted therapies in mRCC patients. Attempts to explain differences in efficacy and toxicity of TKIs by use of genetic variants in genes related to the pharmacokinetics and pharmacodynamics of the drug have been successful. CONCLUSION: Most findings on potential biomarkers have not been validated and therefore biomarker testing to guide choice of therapy and dose in mRCC is not yet feasible.
Authors: Daniel J George; Jean-Francois Martini; Michael Staehler; Robert J Motzer; Ahmed Magheli; Frede Donskov; Bernard Escudier; Sherry Li; Michelle Casey; Olga Valota; Brigitte Laguerre; Allan J Pantuck; Hardev S Pandha; Anup Patel; Maria Lechuga; Alain Ravaud Journal: Clin Cancer Res Date: 2018-11-06 Impact factor: 12.531
Authors: Gracia M Amaya; Rebecca Durandis; David S Bourgeois; James A Perkins; Arsany A Abouda; Kahari J Wines; Mohamed Mohamud; Samuel A Starks; R Nathan Daniels; Klarissa D Jackson Journal: Chem Res Toxicol Date: 2018-06-18 Impact factor: 3.739
Authors: Meta H M Diekstra; Jesse J Swen; Loes F M van der Zanden; Sita H Vermeulen; Epie Boven; Ron H J Mathijssen; Koya Fukunaga; Taisei Mushiroda; Fumiya Hongo; Egbert Oosterwijk; Anne Cambon-Thomsen; Daniel Castellano; Achim Fritsch; Jesus Garcia Donas; Cristina Rodriguez-Antona; Rob Ruijtenbeek; Marius T Radu; Tim Eisen; Kerstin Junker; Max Roessler; Ulrich Jaehde; Tsuneharu Miki; Stefan Böhringer; Michiaki Kubo; Lambertus A L M Kiemeney; Henk-Jan Guchelaar Journal: Cancers (Basel) Date: 2022-06-08 Impact factor: 6.575
Authors: Elizabeth A Burnham; Arsany A Abouda; Jennifer E Bissada; Dasean T Nardone-White; Jessica L Beers; Jonghwa Lee; Matthew J Vergne; Klarissa D Jackson Journal: Chem Res Toxicol Date: 2022-04-28 Impact factor: 3.973
Authors: Cristina Bianchi; Chiara Meregalli; Silvia Bombelli; Vitalba Di Stefano; Francesco Salerno; Barbara Torsello; Sofia De Marco; Giorgio Bovo; Ingrid Cifola; Eleonora Mangano; Cristina Battaglia; Guido Strada; Giuseppe Lucarelli; Robert H Weiss; Roberto A Perego Journal: Oncotarget Date: 2017-12-08